Holen Sie sich die Stockscreener-App
63.58
1.07%
-0.69
Handel nachbörslich:
63.40
-0.18
-0.28%
Schlusskurs vom Vortag:
$64.27
Offen:
$64.31
24-Stunden-Volumen:
1.12M
Relative Volume:
0.64
Marktkapitalisierung:
$3.38B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-38.99M
KGV:
-21.22
EPS:
-2.9966
Netto-Cashflow:
$-24.94M
1W Leistung:
+2.37%
1M Leistung:
+18.58%
6M Leistung:
-9.17%
1J Leistung:
+18.05%
1-Tages-Spanne:
$63.16
$66.00
1-Wochen-Bereich:
$59.68
$66.09
52-Wochen-Spanne:
$41.50
$90.32
Soleno Therapeutics Inc Stock (SLNO) Company Profile
Firmenname
Soleno Therapeutics Inc
Sektor
Branche
Telefon
650-213-8444
Adresse
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Vergleichen Sie SLNO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
63.58 | 3.42B | 0 | -38.99M | -24.94M | -2.9966 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-07 | Eingeleitet | Goldman | Buy |
| 2025-08-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-06-23 | Eingeleitet | TD Cowen | Buy |
| 2025-03-05 | Fortgesetzt | Stifel | Buy |
| 2024-12-02 | Bestätigt | Robert W. Baird | Outperform |
| 2024-12-02 | Bestätigt | Stifel | Buy |
| 2024-09-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-10 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-05 | Eingeleitet | Piper Sandler | Overweight |
| 2024-01-23 | Eingeleitet | Stifel | Buy |
| 2023-11-21 | Fortgesetzt | Guggenheim | Buy |
| 2020-09-29 | Eingeleitet | Guggenheim | Buy |
| 2020-01-10 | Eingeleitet | Craig Hallum | Buy |
| 2019-12-23 | Eingeleitet | Oppenheimer | Outperform |
| 2018-02-13 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Soleno Therapeutics Inc Aktie (SLNO) Neueste Nachrichten
Is Soleno Therapeutics Inc. building a consolidation base2025 Winners & Losers & Risk Managed Investment Strategies - newser.com
Soleno Therapeutics Appoints Mark W. Hahn to Board and Audit Committee - TradingView
How to recover losses in Soleno Therapeutics Inc. stockJuly 2025 Technicals & Smart Allocation Stock Tips - newser.com
Strategies to average down on Soleno Therapeutics Inc.2025 Biggest Moves & Smart Money Movement Tracker - newser.com
Will Soleno Therapeutics Inc. outperform the market2025 Price Action Summary & Reliable Price Breakout Alerts - newser.com
Rosen Law Firm Encourages Soleno Therapeutics, Inc. Investors to Inquire About Securities Class Action InvestigationSLNO - PR Newswire
Soleno Therapeutics appoints biopharma finance veteran to board By Investing.com - Investing.com Nigeria
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc.SLNO - WV News
Using Bollinger Bands to evaluate Soleno Therapeutics Inc.2025 Top Gainers & Safe Entry Momentum Tips - newser.com
Has Soleno Therapeutics Inc. formed a bullish divergenceJuly 2025 Highlights & Fast Entry High Yield Tips - newser.com
Is Soleno Therapeutics Inc. stock entering bullish territoryPortfolio Risk Summary & Stock Market Timing Techniques - newser.com
Multi asset correlation models including Soleno Therapeutics Inc.July 2025 News Drivers & High Conviction Buy Zone Picks - newser.com
Soleno Therapeutics appoints biopharma finance veteran to board - Investing.com India
Soleno Therapeutics Appoints Biopharmaceutical Executive Mark W. Hahn to its Board of Directors - GlobeNewswire
Soleno Therapeutics, Inc. Appoints Mark W. Hahn as an Independent Director to Its Board of Directors and A Member of Its Audit Committee - MarketScreener
Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Exploring an 86% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
SLNO Investor News: If You Have Suffered Losses in Soleno - GlobeNewswire
Soleno drops on death of patient treated with Vykat XR - MSN
SLNO Investor News: If You Have Suffered Losses in Soleno Therapeutics, Inc. (NASDAQ: SLNO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
Soleno Therapeutics stock dips on proposed $200M offering - MSN
Soleno Stock: Blockbuster Launch In Progress (NASDAQ:SLNO) - Seeking Alpha
Soleno Therapeutics (NASDAQ:SLNO) Coverage Initiated by Analysts at The Goldman Sachs Group - MarketBeat
How to use Fibonacci retracement on Soleno Therapeutics Inc.Gap Down & Fast Moving Stock Watchlists - newser.com
Published on: 2025-10-10 05:36:53 - newser.com
Can Soleno Therapeutics Inc. stock deliver sustainable ROEMarket Volume Report & Expert Curated Trade Setup Alerts - newser.com
Soleno Therapeutics (SLNO) Drops Amid Critical Scorpion Report -- Hagens Berman - GlobeNewswire
SOLENO (SLNO) REMINDER: Bragar Eagel & Squire, P.C. Reminds - GlobeNewswire
Published on: 2025-10-09 06:36:22 - newser.com
Will Soleno Therapeutics Inc. bounce back from current supportJuly 2025 Gainers & Capital Protection Trading Alerts - newser.com
What Wall Street predicts for Soleno Therapeutics Inc. stock priceAnalyst Downgrade & Weekly High Return Stock Forecasts - newser.com
Soleno Therapeutics (NASDAQ:SLNO) Given Sell (D-) Rating at Weiss Ratings - MarketBeat
Is Soleno Therapeutics Inc 6XC a good long term investment - earlytimes.in
Piper Sandler Maintains a Buy Rating on Soleno Therapeutics (SLNO), Sets a $145 PT - Yahoo Finance
Soleno Therapeutics (NASDAQ:SLNO) Trading Up 7%Should You Buy? - MarketBeat
Soleno Therapeutics (SLNO): Reassessing Valuation After VYKAT XR Safety Debate and Analyst Support - Yahoo Finance
Goldman Sachs Initiates Soleno Therapeutics at Buy With $125 Price Target - MarketScreener
Soleno Therapeutics Announces Proposed $200 Million Public Offering of Common Stock - GlobeNewswire
Goldman Sachs initiates Soleno Therapeutics stock with Buy rating on Vykat potential - Investing.com
Is Soleno Therapeutics Inc. stock supported by strong cash flows - newser.com
Soleno Therapeutics (SLNO) Is Down 8.9% After Short Seller Targets VYKAT XR Safety and Market Potential – Has The Bull Case Changed? - Sahm
How Soleno Therapeutics Inc. stock performs in rate cut cyclesJuly 2025 Analyst Calls & Safe Entry Point Alerts - newser.com
Detecting support and resistance levels for Soleno Therapeutics Inc.Weekly Stock Recap & Verified Entry Point Signals - newser.com
How Soleno Therapeutics Inc. (6XC) stock stacks up against competitorsMarket Performance Summary & Growth Focused Entry Reports - newser.com
Soleno Therapeutics (SLNO): Assessing Valuation and Growth Potential in the Biotech Sector - Sahm
Piper Sandler reiterates Overweight rating on Soleno Therapeutics stock - Investing.com
How to escape a deep drawdown in Soleno Therapeutics Inc.Trade Exit Summary & Weekly High Return Forecasts - newser.com
Finanzdaten der Soleno Therapeutics Inc-Aktie (SLNO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Soleno Therapeutics Inc-Aktie (SLNO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hirano Patricia C | SEE REMARKS |
Jul 01 '25 |
Sale |
82.76 |
3,830 |
316,971 |
13,206 |
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):